Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
Associated Genetic Biomarkers
NCI Definition: Progression of polycythemia vera characterized by decreased erythropoiesis and granulopoiesis, reticulin and collagen fibrosis of the bone marrow, leucoerythroblastic reaction in the peripheral blood, poikilocytosis, tear-drop shaped red blood cells, and splenomegaly. 
There are 3 clinical trials for polycythemia vera, post-polycythemic myelofibrosis phase, of which 1 is open and 2 are completed or closed. Of the trials that contain polycythemia vera, post-polycythemic myelofibrosis phase as an inclusion criterion, 1 is phase 1 (0 open) and 2 are phase 2 (1 open).
Pacritinib is the most common intervention in polycythemia vera, post-polycythemic myelofibrosis phase clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.